Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Bosotti

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Oncotarget|August 20, 2016
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compoundsDiego Carrella, Isabella Manni, Barbara Tumaini, et al.
British Journal of Cancer|December 4, 2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerAlessio Amatu, Alessio Somaschini, Giulio Cerea, et al.
Journal of Medicinal Chemistry|January 19, 2008
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationshipsErmes Vanotti, Raffaella Amici, Alberto Bargiotti, et al.
Journal of the National Cancer Institute|November 14, 2015
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Elena Ardini, Roberta Bosotti, et al.
Molecular Cancer Therapeutics|March 5, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Maria Menichincheri, Patrizia Banfi, et al.
Molecular Oncology|June 26, 2014
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Oncotarget|August 20, 2016
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compoundsDiego Carrella, Isabella Manni, Barbara Tumaini, et al.
British Journal of Cancer|December 4, 2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerAlessio Amatu, Alessio Somaschini, Giulio Cerea, et al.
Journal of Medicinal Chemistry|January 19, 2008
Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationshipsErmes Vanotti, Raffaella Amici, Alberto Bargiotti, et al.
Journal of the National Cancer Institute|November 14, 2015
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Elena Ardini, Roberta Bosotti, et al.
Molecular Cancer Therapeutics|March 5, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Maria Menichincheri, Patrizia Banfi, et al.
Molecular Oncology|June 26, 2014
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, et al.
Pageof 3